Fed. Circ. Affirms Celltrion, Hospira Didn't Infringe Janssen IP
The Federal Circuit on Thursday upheld a Massachusetts federal judge's ruling that Celltrion Inc. and Pfizer unit Hospira Inc. didn't infringe a patent covering Biotech's blockbuster arthritis biologic Remicade....To view the full article, register now.
Already a subscriber? Click here to view full article